Diabetes Care, Vol 19, Issue 7 744-750, Copyright © 1996 by American Diabetes Association

ARTICLES

The medical management of hyperglycemia over a 10-year period in people with diabetes

R Klein, BE Klein, SE Moss and KJ Cruickshanks
Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison, USA. kleinr@epi.ophth.wisc.edu

OBJECTIVE: The purpose of the study was to examine changes in the medical management of glycemia in diabetes and its relation to changes in hyperglycemia as measured by glycated hemoglobin. RESEARCH DESIGN AND METHODS: A total of 765 patients with younger-onset diabetes diagnosed before 30 years of age and 533 older-onset diabetic patients participated in a population-based study in southern Wisconsin, at baseline (1980-1982), at 4 years (1984-1986), and at 10 years (1990-1992). Glycated hemoglobin, the presence of complications, and information regarding medical management of glycemia, hypoglycemic reactions, and socioeconomic factors were determined using standardized protocols at the three examinations. RESULTS: In the younger-onset group, there was a significant increase (P < 0.001) in the use of three or more insulin injections per day or in the use of an insulin infusion pump from 3.6% of the cohort at baseline to 24.4% at the 10-year follow-up. This increase was associated with female sex, the presence of gross proteinuria, more education, and better glycemic control at baseline. In the older-onset group, there was a significant (P < 0.05) increase in the proportion of patients taking insulin, from 49.2% at baseline to 61.9% at the 10-year follow-up. This was associated with being younger, having a longer duration of diabetes, having higher glycated hemoglobin values, and having more education at baseline, or developing proliferative diabetic retinopathy or macular edema between baseline and the 4-year follow-up. CONCLUSIONS: These data suggest a change in the pattern of use of insulin to treat people with diabetes. However, there is still a large number of individuals with poorly controlled diabetes in the population.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Klein and B. E. K. Klein The Epidemiology of Eye Disease: From Glycemia to Genetics The Friedenwald Lecture Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 1747 - 1753. [Full Text] [PDF]

				D. F. Kruger, C. L. Martin, and C. E. Sadler New insights into glucose regulation. The Diabetes Educator, March 1, 2006; 32(2): 221 - 228. [Abstract] [Full Text] [PDF]

				S. L. Aronoff, K. Berkowitz, B. Shreiner, and L. Want Glucose Metabolism and Regulation: Beyond Insulin and Glucagon Diabetes Spectr, July 1, 2004; 17(3): 183 - 190. [Abstract] [Full Text] [PDF]

				P. A. Hollander, P. Levy, M. S. Fineman, D. G. Maggs, L. Z. Shen, S. A. Strobel, C. Weyer, and O. G. Kolterman Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-year randomized controlled trial Diabetes Care, March 1, 2003; 26(3): 784 - 790. [Abstract] [Full Text] [PDF]

				C. Levetan, L. L. Want, C. Weyer, S. A. Strobel, J. Crean, Y. Wang, D. G. Maggs, O. G. Kolterman, M. Chandran, S. R. Mudaliar, et al. Impact of Pramlintide on Glucose Fluctuations and Postprandial Glucose, Glucagon, and Triglyceride Excursions Among Patients With Type 1 Diabetes Intensively Treated With Insulin Pumps Diabetes Care, January 1, 2003; 26(1): 1 - 8. [Abstract] [Full Text] [PDF]

				S. A. Black Diabetes, Diversity, and Disparity: What Do We Do With the Evidence? Am J Public Health, April 1, 2002; 92(4): 543 - 548. [Abstract] [Full Text]

				F. Whitehouse, D. F. Kruger, M. Fineman, L. Shen, J. A. Ruggles, D. G. Maggs, C. Weyer, and O. G. Kolterman A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes Diabetes Care, April 1, 2002; 25(4): 724 - 730. [Abstract] [Full Text] [PDF]

				R. G. Hiss, M. L. Gillard, B. A. Armbruster, and L. A. McClure Comprehensive Evaluation of Community-Based Diabetic Patients: Effect of feedback to patients and their physicians: a randomized controlled trial Diabetes Care, April 1, 2001; 24(4): 690 - 694. [Abstract] [Full Text]

				D. M. Gorson, M. H. Rusk, S. L. Schwartz, and V. Fonseca Effect of Troglitazone in Type 2 Diabetes Mellitus N. Engl. J. Med., August 6, 1998; 339(6): 406 - 406. [Full Text]

				S. Schwartz, P. Raskin, V. Fonseca, J. F. Graveline, and The Troglitazone and Exogenous Insulin Study Group Effect of Troglitazone in Insulin-Treated Patients with Type II Diabetes Mellitus N. Engl. J. Med., March 26, 1998; 338(13): 861 - 866. [Abstract] [Full Text] [PDF]